Press coverage about Biopharmx Corp (NYSE:BPMX) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biopharmx Corp earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.9822606887665 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/26/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-biopharmx-corp-bpmx-stock-price.html.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Insider Buying and Selling by Quarter for Biopharmx Corp (NYSE:BPMX)

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.